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Anti-neuropathic effects of 
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Traditional uses and current results highlight the neuroprotective properties of Rosmarinus officinalis 
L. The compelling need for novel strategies able to relieve neuropathic pain encouraged us to analyze 
different rosemary leaf extracts in rats following chronic constriction injury (CCI) of sciatic nerve. 
Ethanol, acetone, and the innovative ultrasound-hexane extractive methods were used to obtain: 
EE, AE, and for hexane extracts UREprel and URE. Extracts were characterized in terms of typical 
constituents and repeatedly administered to CCI-rats (13-days treatment, from the day of surgery). URE 
showed the best efficacy and potency in reducing hypersensitivity to noxious- and non-noxious stimuli 
and spontaneous pain. URE contained the higher quantity of the terpenoid carnosic acid (CA) and its 
efficacy was compared to pure CA. Histological analysis of the sciatic nerve revealed that URE prevented 
axon and myelin derangement, edema and inflammatory infiltrate. In the dorsal horn of the spinal 
cord, URE did not reduce astrocyte activation. Both the pain reliever and the neuroconservative effects 
of URE were significantly prevented by the nicotinic receptor (nAChR) antagonist mecamylamine. In 
conclusion, the hexane-ultrasound rosemary extract is able to reduce neuropathic hypersensitivity 
and protect nervous tissues. Effectiveness is mainly related to the terpenoid fraction by mechanisms 
involving nAChRs.
Rosmarinus officinalis L. (Lamiaceae), commonly called rosemary, is woody perennial herb native of the 
Mediterranean region and now widely spread in European countries. It is a common spice used worldwide 
for culinary and medicinal purpose1, not only for the aromatic fraction but also for the typical phenolic com-
pounds. The hydroalcoholic extracts from R. officinalis have been recognized as safe by the European Food Safety 
Authority (EFSA)2 and their use is authorized as natural antioxidants and preservatives of foods. Several biological 
effects have been associated to rosemary leaf extracts (anti-spasmodic3, anti-inflammatory and anti-nociceptive4, 
hepatoprotective5, diuretic6) due to its various phytochemical constituents. The most represented compounds 
are monoterpenes (essential oils), diterpene phenols (carnosic acid, carnosol, rosmanol, epirosmanol, isoros-
manol), phenolic acids (rosmarinic acid), flavonols and triterpene acids (ursolic acid, oleanolic acid, betulinic 
acid)7–11. Among them, carnosic acid (CA) is considered a potent antioxidant useful as protector against free rad-
icals damage together with rosmarinic acid and carnosol12–15. A recent work demonstrated that a hydroalcoholic 
rosemary extract inhibits acetylcholinesterase activity, improving memory impairment in the rat16 furthermore, 
rosemary polyphenols enhanced cholinergic activities in PC12 cells17,18. The cholinergic properties of rosemary 
extracts prompt us to evaluate a possible role in neuropathy treatment since the relevance of the cholinergic 
system modulation in pain signalling19. The efficacy against acute pain is most closely related to the muscarinic 
component20,21, on the contrary the cholinergic relevance in neuropathic pain management is imputable to the 
nicotinic acetylcholine receptors (nAChRs)22. Both the anti-hypersensitive and neuroprotective effects of the 
ACh synthesis promoter acetyl-l-carnitine are blocked by mecamylamine, a nonselective nAChR antagonist22. 
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Moreover, selective modulators of the α 723 and the α 9α 1024 nAChR subtypes relieved nerve trauma-induced pain 
in the rat and prevented nervous system derangement that underlie neuropathies.
Aim of this study was to investigate the efficacy of novel extracts of Rosmarinus officinalis leaves on Chronic 
Constriction Injury (CCI) induced neuropathic pain in the rat, a model of trauma-induced neuropathy representative 
of compressive damage. Different products were obtained by ethanol- (EE), acetone- (AE) or n-hexane-ultrasound 
assisted-extraction (UREprel and URE) to compare properties related to diverse concentrations of phenol derivatives 
and mainly CA. The pain reliever profile as well as the neuroprotective properties were characterized. Finally, the 
pharmacodynamic relevance of nAChRs in rosemary anti-neuropathic activity was assessed.
Results
Composition of the rosemary extracts. Aiming to identify the activity of the different components, a 
fractionation process was applied trying to separate the different group of phenolic compounds typical of rose-
mary leaves.
As previously assessed25 the total phenolic extract was obtained using ethanol (EE), the acetone extract was 
applied to selectively recover terpenoids and several lipophilic flavonoids without containing rosmarinic acid 
(AE); finally, extracts enriched in terpenoids, particularly in CA, were obtained by n-hexane extraction assisted 
by ultrasounds (UREprel and URE). The main phenolic structures of rosemary are visible in the Supplementary 
Figure S1, while representative chromatographic profiles of the extracts are shown in Fig. 1(a–c). EE (Fig. 1a) 
typically contains all the components that characterize the phenolic fraction: rosmarinic acid and other minor 
cinnamoyl derivatives, a group of glycosylated and methoxylated flavonoids and the diterpenoid fraction mainly 
constituted by CA and derivatives25. Acetone was useful to prepare an extract characterized by the absence of the 
polar constituents (mainly rosmarinic acid) and enriched in lipophilic molecules (Fig. 1b). Aimed to obtain a 
CA-enriched extract, and taking into account that CA undergoes toward rapid oxidation processes when in polar 
media26, the n-hexane was chosen as alternative solvent and ultrasounds assisted extraction (UAE) was applied. 
Noteworthy, a traditional liquid/solid extraction carried out by n-hexane was ineffective to recover the terpenoid 
Figure 1. Extracts characterization. HPLC profiles of (a) EE at 330 e 284 nm, (b) AE at 330 nm and (c) URE at 
284 nm. 1, rosmarinic acid, 2, cirsimaritin; 3, genkwanin; 4–5, unknown flavonoids; 6, carnosol; 7, carnosic acid. 
Phenolic distribution in rosemary extracts. (d) Comparison among the total contents in flavonoid, terpenoids 
and total phenols in EE, AE, UREprel and URE. (e) Quantitative determination of rosmarinic acid and main 
flavonoid and terpenoid components. (f) Percentage of flavonoids and carnosol with respect to total phenols in 
UREprel and URE.
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fraction and specifically CA (data not shown). On the opposite, an unexpected positive result was obtained cou-
pling this solvent with ultrasounds (URE, Fig. 1c).
A comparison of the total phenolic content with the distribution of the different chemical subclasses and some 
principal constituents is shown in the left panels of Fig. 1(d–f). Although EE, AE and UREprel showed a similar 
concentration of total phenols (Fig. 1d), flavonoids and, particularly, terpenoids levels were consistently different. 
Progressively, in EE, AE and UREprel flavonoids decreased whereas terpenoids increased (Fig. 1d). Regarding 
UREprel and URE, even if prepared applying the same extractive process, the latter sample shared a lower con-
tent of flavonoids and carnosol (the main oxidation product of CA), but higher levels of CA (191.3 mg g−1 dried 
extract; Fig. 1e). As depicted in Fig. 1f, URE contained lower levels of flavonoids and carnosol (the main oxidation 
product of CA) in comparison to UREprel as evaluated as percentage on total phenols. Other differences among 
extracts are shown in Fig. 1e considering single flavonoids (cirsimaritin and genkwanin) and terpenoid (CA and 
carnosol) constituents. URE and UREprel were compared in vivo using dosages equivalent as CA concentration. 
In particular, 100 mg UREprel contained 13.5 mg CA, 1.5 mg carnosol, 0.7 mg total flavonoids; 70 mg URE con-
tained 13.5 mg CA, 1.3 mg carnosol, 0.5 mg total flavonoids.
Effect of repeated administration of EE and AE on CCI-induced hypersensitivity. Fourteen days 
after sciatic nerve ligation, the weight (noxious mechanical stimulus; Paw pressure test) tolerated on the ipsilat-
eral paw decreased from the value of 66.3 ± 1.1 (sham + vehicle) to 41.2 ± 1.5 g (CCI + vehicle) (Fig. 2a). The 
response of the contralateral paw was unaltered. Daily administration of EE (100–300 mg kg−1) was able to reduce 
the hypersensitivity (to about 55 g) without a dose response effect. AE (100 and 300 mg kg−1) increased pain 
threshold up to about 60 g. Von Frey test let to evaluate the sensitivity to a mechanical non noxious stimulus, the 
baseline withdrawal threshold was significantly decreased 14 days after injury on ipsilateral paw of CCI + vehicle 
group (9.2 ± 0.9 g) in comparison to the control group (24.6 ± 2.1 g) (Fig. 2b). The higher dosage (300 mg kg−1) of 
EE and AE similarly increased the withdrawal threshold of ipsilateral paws, reaching a value of about 16 g, on the 
contrary only AE maintained the efficacy at 100 mg kg−1. As shown in Fig. 2c, the difference between the weight 
burdened on the contralateral and the ipsilateral paw (Δ weight; Incapacitance test) was increased in CCI + vehi-
cle (79.5 ± 4.6 g) in comparison to sham + vehicle (− 3.9 ± 1.1 g) groups. Both treatments with EE and AE (100 mg 
kg−1) reduced by 25% the hind limb weight bearing alterations, the higher dose (300 mg kg−1) reduced the 
Δ weight by 62% (EE) and 70% (AE).
Effect of repeated administration of UREprel, URE and CA on CCI-induced hypersensitivity. 
According to data in Fig. 3, CA was chosen as phytochemical marker to define the dosages of dried samples in 
order to supply an equivalent CA amount (13.5 mg kg−1). On day 7 (after nerve injury), animals tolerated a weight 
of 45.8 ± 0.8 g in comparison to the of sham + vehicle group (64.4 ± 0.6 g) (Fig. 3a, ipsilateral paw). Repeated 
administration of UREprel (100 mg kg−1), URE (70.0 mg kg−1) and CA (13.5 mg kg−1) significantly reduced 
mechanical hypersensitivity (Paw pressure test), reaching values of 50.3 ± 0.5 g, 55.8 ± 0.8 g and 60.6 ± 0.6 g, 
respectively. On day 14, efficacy increased maintaining the order CA > URE > UREprel. In particular, URE and 
CA were able to fully prevent hypersensitivity, CA further increased the threshold up to value higher than con-
trol (Fig. 3a). Similar results were obtained by the Von Frey test (Fig. 3b). On Day 7, the withdrawal threshold to 
mechanical non noxious stimuli of CCI + vehicle rats was decreased to 12.7 ± 0.6 g (ipsilateral paw). Repeated 
administration of 100 mg kg−1 UREprel or 70.0 mg kg−1 URE increased the pain threshold up to 16.4 ± 0.5 g and 
18.1 ± 0.5 g, respectively. CA (13.5 mg kg−1) enhanced the effect to 20.0 ± 0.3 g (Fig. 3b). As shown in Fig. 3c, the 
hypersensitivity to a thermal noxious stimulus (Plantar test) decreased the baseline level of CCI + vehicle animals 
(9.0 ± 1.1 s; ipsilateral paw) to 6.2 ± 0.6 s on day 7 and 6.7 ± 0.5 s on day 14. CA was the only treatment able to 
prevent thermal hyperalgesia on day 7 whereas on day 14, URE and CA showed a comparable effect (Fig. 3c). 
UREprel did not induce a significant effect. None of rosemary extracts influenced the pain threshold of the con-
tralateral paw in comparison to the control group (data not shown).
Finally, CCI induced similar hind limb weight bearing alterations induced on days 7 and 14 (Fig. 3d). URE 
and CA relieved postural imbalance by 57% and 62%, respectively, on day 7 and fully prevented the alteration on 
day 14. UREprel was efficacious on day 14 (Fig. 3d). Significantly different effects induced by CA in comparison to 
URE prel are indicated in Fig. 3; the responses to URE and CA were not significantly different.
Figure 4 shows the percentage of reduction of URE effect in the presence of mecamylamine in the Paw pres-
sure, Von Frey, Plantar and Incapacitance tests. Both on days 7 and 14, mecamylamine prevented URE efficacy by 
about 60–80%. Absolute values are reported in the Supplementary Figure S2a–d. Mecamylamine did not alter the 
baseline threshold of the contralateral paw (data not shown).
Effect of acute administration of URE and CA on CCI-induced hypersensitivity. Effects of a single 
administration of URE and CA were evaluated over time on day 14 after CCI (Fig. 5a). In the Paw pressure test, 
70 mg kg−1 URE p.o. reduced mechanical hypersensitivity by 70% peaking 15 min after treatment, at the same 
time 13.5 mg kg−1 CA reduced by 85%. Effects lasted 45 and 30 min for URE and CA, respectively (Fig. 5a). A sim-
ilar efficacy profile was shown in decreasing the hind limb weight bearing alterations (Incapacitance test; Fig. 5b).
The pre-treatment with mecamylamine (2 mg kg−1 i.p., 30 min before URE) significantly reduced the 
acute anti-hyperalgesic effect of URE (70.0 mg kg−1 p.o.) as well as the improvement of postural unbalance. 
Mecamylamine significantly reverted CA (13.5 mg kg−1 p.o.) acute efficacy in both tests (Fig. 5a,b).
Effect of repeated administration of URE on CCI-induced sciatic nerve damage: histological 
evaluation. Morphometric evaluations on osmium-fixed nerves allowed to measure the number of fibers, 
fiber diameter, axon diameter and myelin thickness, discriminating between large and small fibers (stratified by 
diameter in ≥ 6 μ m and < 6 μ m). To better characterize the CCI-induced alterations, 3 distances (300, 900 and 
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1800 μ m) were evaluated starting from the ligation in the proximal part of the nerve (Supplementary Figure S3). 
On day 14, CCI decreased all nerve structural parameters of large fibers with a gradually less intensity from 300 μ m 
to 1800 μ m (Table 1). The number of small fibers increased independently by the distance to ligation (Table 1). 
Since the significant but middle damage, 900 μ m was chosen as optimal nerve distance for evaluating the effect of 
URE repeated treatment. As depicted in Fig. 6, URE (70 mg kg−1 p.o. daily starting from the day of surgery) was 
able to completely restore the myelin sheet of large fibers. The fiber diameter as well as the number of fibers were 
also significantly increased. As regards the small fibers, URE increased myelin thickness and reduced the number 
of fibers. The co-treatment with mecamylamine (2 mg kg−1 i.p. bid starting from the day of surgery) significantly 
reduced the protective effect of URE on both large and small fibers (Fig. 6).
As shown in Fig. 7, hematoxylin staining revealed an abundant inflammatory infiltrate and a massive presence 
of edema among the fibers of CCI animals (900 μ m). URE reduced both phenomena by about 50% in a partially 
mecamylamine-dependent manner (Figs 7 and 8).
The spinal cord was analyzed to assess astroglial cells reorganization 14 days after ligation. Astrocytes were 
recognized by immunohistochemistry against glial fibrillary acidic protein (GFAP) (Fig. 9a). As shown in Fig. 9b, 
GFAP-positive cells significantly increased in the superficial laminae of the ipsilateral dorsal horn in CCI rats. 
The chronic treatment with URE did not modify astrocytes activation. On the contrary, the co-treatment with 
Figure 2. Effects of EE and AE on pain behaviours induced by CCI. (a) Sensitivity to a noxious mechanical 
stimulus as measured by the Paw-pressure test. (b) Pain threshold to a non-noxious mechanical stimulus as 
measured by the Von Frey test. (c) Pain assessed by hind limb weight bearing alterations using an Incapacitance 
test; data are expressed as the difference between the weight applied on the limb contralateral to the injury 
and the weight applied on the ipsilateral limb. Behavioural tests were performed 14 days after operation, 
24h after the last treatment. Vegetal extracts were administered p.o.; control animals were subjected to sham 
surgery and treated with vehicle. Treatments were performed daily starting on the day of surgery. Each value 
represents the mean ± SEM of 10 rats per group, performed in 2 different experimental sets. ^^^P < 0.001 versus 
sham + vehicle; *P < 0.05, **P < 0.01 and ***P < 0.001 versus CCI + vehicle.
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Figure 3. Effects of UREprel, URE and CA on pain behaviours induced by CCI. (a) Sensitivity to a noxious 
mechanical stimulus as measured by the Paw-pressure test. (b) Pain threshold to a non-noxious mechanical 
stimulus as measured by the Von Frey test. (c) Sensitivity to a noxious thermal stimulus as measured by 
the Plantar test. (d) Pain assessed by hind limb weight bearing alterations using an Incapacitance test. All 
behavioural tests were performed 7 and 14 days after operation, 24 h after the last treatment. Vegetal extracts 
and CA were administered p.o. and i.p., respectively; control animals were subjected to sham surgery and 
treated with vehicle. Treatments were performed daily starting on the day of surgery. Each value represents 
the mean ± SEM of 10 rats per group, performed in 2 different experimental sets. ^^^P < 0.001 versus 
sham + vehicle; *P < 0.05, **P < 0.01 and ***P < 0.001 versus CCI + vehicle; §P < 0.05 versus CCI + UREprel.
Figure 4. Effects of mecamylamine on the anti-hypersensitive effects URE. Percentage of the inhibition 
induced by mecamylamine on the effects evoked by URE (considered as 100%) in the Paw-pressure, Von Frey, 
Plantar and Incapacitance tests. All behavioural tests were performed 7 and 14 days after operation, 24 h after 
the last treatment. URE was administered daily p.o.; mecamylamine was injected i.p. bid. Treatments started 
on the day of surgery. Each value represents the mean ± SEM of 10 rats per group, performed in 2 different 
experimental sets. °°P < 0.01 versus CCI + URE without mecamylamine. Absolute values are reported in the 
Supplementary Figure S2a–d.
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URE and mecamylamine prevented the increase of GFAP-positive cells in comparison to CCI + vehicle and 
CCI + URE groups (Fig. 9a,b).
Discussion
In this report, we showed that extracts from Rosmarinus officinalis are able to control pain by inhibiting its pro-
gression during a persistent noxious condition. As a pivotal characteristic, rosemary extract prevents damage 
to the nervous system. Thus, rosemary exerts effects on the origins of neuropathic pain and offers a means to 
directly modulate nervous signaling. The anti-neuropathic effects are mainly due to the terpenoid fraction in a 
mecamylamine-reversed manner suggesting a pharmacodynamic role of nAChRs.
In recent years increasing attention is deserved to the therapeutic use of plants also in chronic pathologi-
cal conditions related to severe alterations of the nervous system27. The scientific and clinical relevance of this 
approach is often compromised by evidences of activity obtained with not standardized procedures and referred 
to vegetal products scarcely characterized as extraction methods, chemical composition and pharmacodynamic 
profile. In the present work we obtain a pharmacologically relevant product starting from the historic and popular 
use of rosemary to relieve pain28.
Selected extracts from rosemary leaves have been produced, characterized and compared in terms of phenolic 
composition to define the more active constituents. EE, AE, UREprel and URE contain a progressively decreas-
ing rosmarinic acid and flavonoids component concentration while the terpenoids content increases. In rats 
underwent the loose ligation of the sciatic nerve, AE shows higher pain relieving efficacy in comparison to EE 
suggesting the pharmacodynamic role of terpenoids and the minor relevance of rosmarinic acid. Prompted to 
obtain fractions more enriched in terpenoids, UREprel and URE were produced through UAE by n-hexane. The 
extraction method is clean, the low bulk temperature and the rapid execution avoid degradative processes and 
greatly accelerate the extraction procedure. Generally, the use of ultrasounds offers several advantages in terms 
Figure 5. Acute effects of URE and CA on pain behaviours induced by CCI. On day 14 after operation, URE 
extract (p.o.) and CA (i.p.) were administered in the presence or in the absence of a pre-treatment (− 30 min) 
with mecamylamine (meca; i.p.). (a) Sensitivity to a noxious mechanical stimulus as measured by the Paw-
pressure test. (b) Pain assessed by hind limb weight bearing alterations using the Incapacitance test. Control 
animals were subjected to sham surgery and treated with vehicle. Each value represents the mean ± SEM of 
10 rats per group, performed in 2 different experimental sets. ^^^P < 0.001 versus sham + vehicle; *P < 0.05, 
**P < 0.01 and ***P < 0.001 versus CCI + vehicle; °P < 0.05 and °°P < 0.01 versus CCI + URE or CCI + CA.
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of higher yields and higher selectivity, improves the processing time, reduces chemical and physical hazards29. 
Ultrasounds have been recognized for potential industrial application in the phyto-pharmaceutical extraction for 
a wide range of herbal extracts. To the best of our knowledge, this is the first application of n-hexane by UAE to 
selectively recover the terpenoids from rosemary leaves.
UREprel and URE profiles were analyzed in vivo employing dosages equivalent in CA content (as a conse-
quence with lower content of flavonoids and carnosol for URE). Repeated administrations were able to reduce the 
development of CCI-dependent painful response to suprathreshold stimulation and to increase pain threshold 
to non-noxious stimuli. Both extracts also reduced postural unbalance, a feature of neuropathy progression, as 
measured by hind limb weight bearing alterations. This measure, in particular, may asses the somatosensory 
component of neuropathy highlighting spontaneous, non-evoked pain24. UREprel and URE are more potent and 
efficacy than AE (300 mg kg−1 vs 100 and 70 mg kg−1, respectively). The fundamental role of CA was confirmed 
since 13.5 mg kg−1 CA (as standard compound) is fully effective. Nevertheless, differences may be highlighted 
among UREprel and URE and pure CA effects. An improvement of the anti-neuropathic efficacy of these prod-
ucts was obtained by increasing CA concentration (CA > URE > UREprel) to the detriment of other components 
suggesting the possibility that rosemary extracts contains compounds able to partially reduce CA activity. On the 
other hand, activity differences of CA and carnosol remain to be clarified.
URE and CA shows anti-hypersensitive effect also after a single administration accordingly to previous evi-
dence of acute anti-nociceptive, anti-inflammatory and anti-neuropathic efficacy of rosemary extracts (alcoholic 
or hydroalcoholic)4,12, essential oil30,31 and CA32. CA presents anti-inflammatory and anti-oxidant properties 
since it is able to activate the transcription factor NF-E2-related factor 2 (Nrf2) that in turn mediates transcription 
of antioxidant/cytoprotective genes by binding to the antioxidant-response element (ARE)13. Neuroprotective 
effects of CA are reported both in vitro and in vivo33,34 and the relationship existing between redox unbalance 
and neuropathy35,36 suggests the utility of a Nrf2-ARE activator in CCI-induced hypersensitivity. Moreover, CA 
has been recently described as able to inhibit the AChE activity16,37 and enhance cholinergic activities17. This bio-
logical property accounts for the rosemary efficacy against memory impairment and further hints an additional 
anti-neuropathic mechanisms since the role of the cholinergic system in pain modulation19,38,39. We extensively 
studied the functions of cholinergic system in pain modulation highlighting the relevance of nAChRs in neuro-
pathic pain relief22–24,40. In the present results, the nAChR antagonist mecamylamine significantly reduced the 
anti-hypersensitive effects of both URE and CA indicating a novel pharmacodynamic mechanism for rosemary 
and its terpenoid component.
The pain-relieving effect of URE and CA progressively increased during treatment suggesting a rescue mech-
anism that protects nervous tissue from the damages that result in chronic pain. CCI induced morphometric 
alterations of the sciatic nerve, consistent with previous reports23,24,41. Furthermore, in the present results we ana-
lyzed the sciatic nerve at different distances from the injury individuating 900 μ m as optimal to evaluate damage 
characteristics and protective effect promoted by treatments. Repeated administrations of URE preserve number 
and diameter of nerve fibers and significantly prevents the reduction in both myelin sheet thickness and axonal 
diameter.
CCI-mediated derangement of nerve morphology is accompanied by a profound local inflammatory reaction 
that includes edema, infiltration of hematogenous immune cells and the induction of various soluble factors such 
as cytokines and chemokines23,24,41,42. Treatment with URE attenuates the degree of peripheral nerve inflamma-
tion, reducing edema and infiltrate suggesting synergy between the anti-inflammatory and the neuroprotective 
effects of this extract. Accordingly to the neuroprotective properties of nAChR-mediated signals22–24,40,43, the URE 
neuroconservative effects are strongly impaired by mecamylamine pretreatment.
Finally, damaged peripheral nerves evoke pain-mediating pro-inflammatory and neurotoxic signals in the 
CNS44. Electrical and chemical stimuli promote complex cascades in intracellular transduction pathways that 
participate in alteration of neuronal and glial functions and subsequently lead to central sensitization45. Plasticity 
of glial cells in spinal cord and brain areas have been recognized as powerful modulators of pain46–48, in par-
ticular astrocytes may be involved in pain maintenance46. In the dorsal horn of CCI rats, we detect an increased 
density of astrocytes (GFAP-positive cells) which URE does not prevent. This data agrees with previous evi-
dence of the nAChR capability to reduce neuropathic pain and induce neuroprotection concomitantly to glial 
distance to 
ligation
Large fibers Small fibers
treatment
number of 
fibers fiber diameter axon diameter
myelin 
thickness treatment
number of 
fibers
fiber 
diameter
axon 
diameter
myelin 
thickness
300 μ m
sham + vehicle 509.8 ± 23.5 10.67 ± 0.08 6.76 ± 0.03 1.95 ± 0.03 sham + vehicle 23.7 ± 4.5 5.10 ± 0.21 3.59 ± 0.23 0.85 ± 0.11
CCI + vehicle 273.3 ± 45.3^ 8.05 ± 0.23^^ 5.93 ± 0.17^^ 1.06 ± 0.03^^ CCI + vehicle 217.0 ± 50.0^ 4.80 ± 0.08 3.33 ± 0.18 0.73 ± 0.06
900 μ m
sham + vehicle 500.8 ± 19.5 10.23 ± 0.1 6.8 ± 0.05 1.93 ± 0.03 sham + vehicle 40.5 ± 7.6 5.1 2 ± 0.15 3.61 ± 0.15 0.82 ± 0.09
CCI + vehicle 336.5 ± 2.0^ 8.04 ± 0.07^^ 5.85 ± 0.01^^ 1.09 ± 0.01^^ CCI + vehicle 240.7 ± 70^ 5.13 ± 0.86 2.91 ± 0.21 0.83 ± 0.07
1800 μ m
sham + vehicle 505.3 ± 20.2 10.40 ± 0.08 6.70 ± 0.08 1.98 ± 0.05 sham + vehicle 33.7 ± 3.5 5.10 ± 0.21 3.57 ± 0.17 0.83 ± 0.10
CCI + vehicle 353.5 ± 49.5^ 9.33 ± 0.43^^ 6.06 ± 0.13^^ 1.63 ± 0.14^^ CCI + vehicle 143.7 ± 23.7^^ 4.88 ± 0.10 3.09 ± 0.08 0.89 ± 0.01
Table 1.  Morphometric evaluations of nerve alterations at progressive distances from CCI. Morphometric 
measurements of number of fibers, fiber diameter, axon diameter and myelin thickness on small and large fibers 
from sciatic nerves of sham + vehicle and CCI + vehicle (day 14 after surgery). Five μ m transverse sections of 
osmium fixed nerves were analyzed. Each value represents the mean ± SEM of 6 rats per group, performed in 2 
different experimental sets. ^P < 0.05 and ^^P < 0.01 versus sham + vehicle.
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Figure 6. Effects of URE on nerve morphological alterations induced by CCI. URE (70 mg kg−1, p.o., daily) 
and mecamylamine (meca, 2.0 mg kg−1, i.p., bid) were administered starting on the day of surgery. On day 14, 
24 h after the last treatment, 5 μ m nerve sections of osmium fixed sciatic nerves collected 900 μ m proximally 
to the injury were analyzed. Ligated nerves (CCI) were compared with nerve of sham-operated animals. Effect 
of repeated administration of URE + vehicle or URE + mecamylamine on the number of fibers, fiber diameter, 
axon diameter and myelin thickness of large and small fibers are shown. Quantitative analysis was performed 
evaluating 6 animals for each group. Each value represents the mean ± SEM of 6 rats per group, performed in 
2 different experimental sets. ^P < 0.05 and ^^P < 0.01 versus sham + vehicle; *P < 0.05 and **P < 0.01 versus 
CCI + vehicle; °°P < 0.01 versus CCI + URE.
www.nature.com/scientificreports/
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cell activation40,49. Since neuroconservation is one of the housekeeping functions of glia50 the nAChRs modu-
lation seems to influence the maladaptive plasticity of glial cells reducing pain and favouring neurorestoration. 
Accordingly, astrocyte activation is reduced in the presence of mecamylamine, the nAChR antagonist able to 
prevent both the pain relieving and the neuroprotective effects of URE.
As regards the safety profile, oleoresins of rosemary, characterized by a high concentration of these terpenoids, 
are frequently used as natural food preservative. The EFSA panel has accepted a NOAEL (No Observed Adverse 
Effect Level) value in the range of 20–60 mg kg−1 of carnosic acid plus carnosol in the rat2. The ADI (Acceptable 
Food Intake) has not been defined but the EFSA opinion is that the margin of safety is high enough to conclude 
that dietary exposure is not of safety concern2.
In conclusion, the selected rosemary extract URE, obtained by an innovative extraction process, is able to 
control pain and prevent alterations of the nervous system induced by nerve injury. The present data offer a pre-
clinical evaluation for a prospective industrial scale up and therapeutic application.
Material and Methods
Plant material. Tissue samples were collected from a clone of Rosmarinus officinalis L. derived from a 
mother plant growing at Montebenichi (Florence). This clone is growing in an experimental rosemary clone 
plantation established in 2010 at the Santa Paolina experimental farm of the Trees and Timber Institute, National 
Research Council in Follonica (GR), Italy. About 1.5 kg of fresh foliar tissue representing the plant leaf population 
of the rosemary clone was used for the preparation of the extracts. Aliquot samples of fresh leaves were dried at 
room temperature in the dark for several days (water content about 45%); both fresh and dried leaves were used 
for the extraction. In particular, two batches of dried leaves, collected in successive months from the same plants, 
were used to prepare the n-hexane extracts by ultrasounds (UREprel and URE) as described below.
Figure 7. Light micrographs of transverse sections of osmium fixed sciatic nerve after hematoxylin  
staining. Panels illustrate the effects of URE repeated treatments. (a) Sham + vehicle; (b) CCI + vehicle;  
(c) CCI + URE; (d) CCI + URE + mecamylamine (meca) on day 14. Five μ m nerve sections collected 900 μ m 
proximally to the injury were analyzed.
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Preparation of the ethanol (EE) and acetone (AE) extracts. For the preparation of the EE extract, 
fresh leaves (close to 80 g) were dipped in liquid nitrogen and immediately finely grounded in a lab mill. As 
already described in our previous study25 the powder was extracted twice with ethanol alternating magnetic stir-
ring and sonication, with a final yield of 10.5% on dried extract.
AE was obtained extracting dried leaves with acetone for 2 h at room temperature (extractive ratio 1 g/6 mL); 
the sample was filtered after the extraction, then a base (NH3) was added (until pH range 8–9) to deprotonate the 
carnosic acid and makes the carnosic acid salt. The precipitated impurities were removed by centrifugation and 
the solution was then acidified (formic acid, pH range 2–3) to induce the precipitation of the terpenoidic fraction 
recovered by centrifugation51. The precipitate was the AE extract with a final yield of 1.6%.
Preparation of the n-hexane extracts (UREprel and URE). The n-hexane extracts were obtained using 
UAE applied on dried leaves (about 150 g). UREprel was from the first batch and URE was obtained from the sec-
ond batch of dried leaves collected after five months. To minimize the variability we purchased the second batch 
of fresh material from the same mother plant then applying the same drying process. Concerning the two batches 
was impossible to guarantee the same ratio young/old leaves. Overall, the harvesting time and the phenological 
state were the main determinants of the differences between UREprel and URE as shown in Fig. 1.
The extraction was carried out by means of a probe system (Danacamerini - Turin) equipped with a tita-
nium horn (Ø = 15 mm) with a conical tip (Ø = 25 mm) working at 19.5 kHz (140 W). Wider tip diameters have 
Figure 8. Effects of URE on edema and infiltration of the sciatic nerve induced over 14 days of CCI. Five μ m 
nerve sections of osmium fixed nerves (900 μ m proximally to the injury) were hematoxylin stained. (a) The 
presence of inflammatory infiltrate was evaluated and quantified by an arbitrary scale starting from 1, mild 
infiltrate up to 10, severe infiltrate. (b) The presence of edema was evaluated and quantified by an arbitrary scale 
starting from 1, mild edema up to 10, widespread edema. Effect of repeated treatment with URE (70 mg kg−1, 
p.o., daily) or URE plus mecamylamine (meca, 2.0 mg kg−1, i.p., bid) was scored in the proximal tract of the 
ipsilateral ligated nerve and compared with sciatic nerves of sham-operated animals. Semi-quantitative analysis 
was performed evaluating 6 animals for each group. Each value represents the mean ± SEM of 6 rats per group, 
performed in 2 different experimental sets. ^^P < 0.01 versus sham + vehicle; **P < 0.01 versus CCI + vehicle; 
°P < 0.05 versus CCI + URE.
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less amplitude but can accommodate larger extraction volumes ensuring a more homogeneous sonication; the 
extractive ratio was 1 g dried leaves/10 mL n-hexane with 10 minutes as extraction time. The reproducibility of 
the extraction was evaluated over time, and both UREprel and URE extracts showed a final yield of 6.3% on dried 
leaves52.
Characterization of the extracts. All the obtained extracts were characterized by HPLC/DAD/MS 
according to Bellumori et al.53. Each extract was dissolved in a definite volume of suitable solvent and the clear 
solutions directly analysed by an HP 1100 L liquid chromatograph equipped with a DAD detector coupled to a 
TOF mass spectrometer with an electrospray (ESI) interface (Agilent Technologies, Palo Alto, CA, USA).
A Fusion, RP18 column (150 mm × 2 mm i.d., 4 μ m) with a precolumn of the same phase (Phenomenex, 
USA), was used. A multi-step linear solvent gradient was applied with mobile phases (A) 0.1% formic acid/water 
and (B) CH3CN. The method started from 0–15 min 15–25% B; 15–25 min 25–35% B; 25–35 min 35–50% B; 
35–40 min 50–100% B with a final plateau of 8 min at 100% B; equilibration time 10 min; flow rate 0.2 mL min−1 
and oven temperature 26 °C; injection volume 5 μ L. The mass spectra were acquired applying the same HPLC 
method and working in negative and positive way with different energy for fragmentation (150–200 V).
Quantitative determination. The determination of phenolic compounds was performed using 2 external 
standards, rosmarinic acid at 330 nm and carnosic acid at 284 nm. The first molecule was also used to quantify the 
flavonoids, and carnosic acid was used to determine all the other diterpenoids. Calibration curve of rosmarinic 
acid (purity grade 96% by Sigma-Aldrich) was in a linearity range between 0.1 μ g and 9.4 μ g with an r2 0.9999; 
the curve of carnosic acid (purity grade 97% by Sigma-Aldrich) was in the linearity range of 0.05–3.4 μ g with an 
r2 0.9998.
Figure 9. Glial profile in spinal cord scored with GFAP-positive cells 14 days after surgery. URE (70 mg 
kg−1, p.o., daily) and mecamylamine (2.0 mg kg−1, i.p., bid) were administered starting on the day of surgery. 
The number of GFAP-positive cells was evaluated in the ipsilateral dorsal horn hemisection of the lumbar 
tract. In the upper panel, representative transverse sections of spinal cord imaged with 20X objective of (a) 
sham + vehicle; (b) CCI + vehicle; (c) CCI + URE; (d) CCI + URE + mecamylamine (meca). Quantitative 
analysis of cellular density was performed evaluating 6 animals for each group. Each value represents the mean 
± SEM of 6 rats per group, performed in 2 different experimental sets. ^P < 0.05 versus sham + vehicle; *P < 0.05 
versus CCI + vehicle.
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The flavonoid content was also estimated by the calibration curve of genkwanine (purity grade ≥ 95% by 
Extrasynthese); a five point calibration curve was obtained (range 0 to 0.85 μ g) with an r2 0.9999. By comparing 
the calibration curves of genkwanin and rosmarinic acid at 330 nm, it was estimated that the flavonoids evaluated 
by the curve of rosmarinic acid give higher values of 68% respect to those from the curve of genkwanin. In this 
work, to simplify the analytical approach, taking into account that the use of genkwanin to determine all flavo-
noids is an approximation, and in agreement with our previous studies25,52,53, the flavonoid content was expressed 
only by the calibration curve of rosmarinic acid.
Animals. Sprague-Dawley rats (Harlan, Varese, Italy) weighing approximately 200–250 g at the beginning 
of the experimental procedure, were used. Animals were housed in CeSAL (Centro Stabulazione Animali da 
Laboratorio, University of Florence) and used at least one week after their arrival. Four rats were housed per cage 
(size 26 × 41 cm); animals were fed a standard laboratory diet and tap water ad libitum, and kept at 23 ± 1 °C 
with a 12 h light/dark cycle, light at 7 a.m. All animal manipulations were carried out according to the European 
Community guidelines for animal care (DL 116/92, application of the European Communities Council Directive 
of 24 November 1986 (86/609/EEC). The ethical policy of the University of Florence complies with the Guide for 
the Care and Use of Laboratory Animals of the US National Institutes of Health (NIH Publication No. 85–23, 
revised 1996; University of Florence assurance number: A5278-01). Formal approval to conduct the experiments 
described was obtained from the Animal Subjects Review Board of the University of Florence. Experiments 
involving animals have been reported according to ARRIVE guidelines54. All efforts were made to minimize 
animal suffering and to reduce the number of animals used.
Induction of peripheral mononeuropathy by CCI. Neuropathy was induced according to the procedure 
described by Bennett and Xie55 Briefly, rats were anaesthetized with 2% isoflurane. Under aseptic conditions, the 
right (ipsilateral) common sciatic nerve was exposed at the level of the middle thigh by blunt dissection. Proximal 
to the trifurcation, the nerve was carefully freed from the surrounding connective tissue, and four chromic cat 
gut ligatures (4–0, Ethicon, Norderstedt, Germany) were tied loosely around the nerve with about a 1 mm spacing 
between ligatures. After hemostasis was confirmed, the incision was closed in layers. The animals were allowed 
to recover from surgery and then housed one per cage with free access to water and standard laboratory chow. 
Another group of rats were subjected to sham surgery in which the sciatic nerve was only exposed but not ligated. 
The CCI model of mononeuropathy elicits a pain syndrome, characterized by increased response to suprathresh-
old stimulation, that begins about 3 days after nerve injury and reaches a plateau that lasts between days 7 to 3024. 
Starting from this data, behavioural measurements were performed on days 7 and 14.
Treatments and measurements. EE and AE extracts were suspended in 1% carboxymethylcellulose 
sodium salt (CMC) and both administered daily per os (p.o.) at the doses of 100 mg kg−1and 300 mg kg−1 for 
13 days, starting from the day of the surgery. Behavioural tests were performed on day 14, 24 h after the last com-
pounds administration. Control rats were treated daily with 1% CMC.
The more lipophilic sample UREprel and URE and the pure CA standard (Sequoia Research, UK; purity grade 
> 97%), were suspended in peanut oil and orally (p.o.) administered starting from the day of surgery at the dos-
ages (equivalent in CA concentration) of 100 mg kg−1, 70 mg kg−1 and 13.5 mg kg−1, respectively. Mecamylamine 
(Sigma-Aldrich, Italy; 2 mg kg−1, dissolved in saline solution) was administered bis in die (bid) intraperitoneally 
(i.p.) in co-treatment with URE (30 min before and 8 h after URE administration) for repeated treatment experi-
ments. Behavioural tests were performed at days 7 and 14, 24 h after the last compounds administration. Control 
animals were treated with vehicles that consisted in peanut oil or saline daily p.o.
Acute treatment experiments were performed on day 14. URE (70 mg kg−1) and CA (13.5 mg kg−1) were 
administered p.o.; mecamylamine (2 mg kg−1) was administered i.p. 30 min before URE. Control animals were 
treated p.o. with vehicles.
Behavioral tests were performed 7 or 14 days after surgery using different experimental approaches to evaluate 
the different clinical components of pain. Mechanical and thermal stimuli were applied to mimic the diverse 
source of pain in human as well as non noxious and noxious stimuli were used to mimic the clinical perceptions 
termed allodynia and hyperalgesia, respectively.
Paw pressure test. The nociceptive threshold in the rat was determined with an analgesimeter (Ugo Basile, 
Varese, Italy), according to the method published by Leighton et al.56 and previously extensively described24.
Von Frey Test. The animals were placed in 20 × 20 cm plexiglas boxes equipped with a metallic meshy floor, 
20 cm above the bench. A habituation of 15 minutes was allowed before the test. An electronic Von Frey hair unit 
(Ugo Basile, Varese, Italy) was used following a method previously described24,57.
Incapacitance test. Weight bearing changes were measured using an incapacitance apparatus (Linton 
Instrumentation, UK) detecting changes in postural equilibrium after a hind limb injury58. The methodology was 
described in Di Cesare Mannelli et al.24. Data are expressed as the difference between the weight applied on the 
limb contralateral to the injury and the weight applied on the ipsilateral one (Δ Weight).
Plantar test. The Hargreaves radiant heat method59 was carried out as modified by Tao et al.60. The rats 
were placed individually in clear plastic chambers of Ugo Basile plantar test apparatus for 20 minutes prior to the 
experiment for the purpose of adaptation. Heat stimulation was applied at IR 60 (infrared intensity 60) on the paw 
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with a 30-second cut-off time. The paw withdrawal latency comprised the time from the start of the beam light 
until the animal withdrew the paw from the heat stimulus (reaction time) was measured.
Tissue explant. On day 14, animals were sacrificed and the ipsilateral sciatic nerves, 0.5 cm proximal to the 
ligation, were explanted; the portion containing the ligature was eliminated. Contralateral nerves and nerves from 
sham-operated animals were also dissected and equivalent portions were collected.
L4/L5 segments of the spinal cord, exposed from the lumbovertebral column via laminectomy and identified 
by tracing the dorsal roots from their respective dorsal root ganglia, were collected.
Osmic acid staining. The sciatic nerve was stored in a 4% glutaraldehyde solution. The tissue samples were 
osmicated in 1% solution of osmium tetroxide for 2 h under constant agitation. Before and after osmication, the 
tissue was repeatedly rinsed in 0.1 M sodium cacodylate at pH 7.4. After gradual dehydratation in ethanol, the 
osmicated nerve samples were embedded in paraffin (Diapath, Milan, Italy). Transverse 5 μ m sections were cut 
on a Reichert microtome (Leica,Rijswijk, The Netherlands), mounted with Canada balsam and observed under 
a light microscopy.
Morphometric analysis. Morphometry was performed on cross sections of osmium fixed sciatic nerves 
300 μ m, 900 μ m, and 1800 μ m from the ligation in the proximal part. In uninjured control nerves, morphometry 
was carried out at the corresponding proximal or distal level to the injury. Counts and measurements were per-
formed using an image analysing software (ImageJ 1.48). Micrographs to be analysed were taken using Nikon 
Olympus BX40 and a 400X objective equipped with NIS F3.00 Imaging Software® . Micrographs were randomly 
selected in non-overlapping areas to cover 50–75% of the total cross-sectional area of the nerve. The total fiber 
diameter (D), the diameter of the axon (d), and the myelin thickness ([D-d]/2) were measured for each nerve. The 
number of small fibers, defined as fibers < 6 μ m, and large fibers, ≥ 6 μ m, was calculated. Since the high degree 
of degeneration showed by the distal part of the nerve we avoid to report the quantitative measurements of this 
portion.
Infiltrate and edema evaluation. Osmium post-fixed sections were stained with hematoxylin and the 
quantity of infiltrate and edema was evaluated. Images were acquired as previously reported in the section 
“Morphometric analysis”. Micrographs were randomly selected in non-overlapping areas to cover 50–75% of the 
total cross-sectional area of the nerve. The sections were semi-quantified by an arbitrary scale starting from 1, 
mild infiltrate and edema up to 10, severe infiltrate and widespread edema. The procedure was carried out by an 
independent researcher who was masked to the experiment.
Immunohistochemical assessment of astrocytes in spinal cord. Fourteen days after surgery, L4/
L5 segments of the spinal cord, exposed from the lumbovertebral column via laminectomy and identified by 
tracing the dorsal roots from their respective DRG, were analyzed to assess astroglial cells. Ten-μ m cryostat sec-
tions of formalin-fixed spinal cord were incubated with primary antibody directed against GFAP (rabbit, 1:1000; 
Dako, Glostrup, Denmark) for astrocytes staining o.n. at 4 °C. After rinsing in phosphate-buffered saline with 
Tween-20, sections were incubated in donkey anti-rabbit immunoglobulin G secondary antibody labeled with 
Alexa Fluor 568 (1:1000, Invitrogen) at room temperature for 1 h. For all immunohistochemical studies, nega-
tive control sections (no exposure to the primary antisera) were processed concurrently with the other sections. 
Quantitative analysis of GFAP-positive cells was performed by collecting at least 3 independent fields through 
a 20 × 0.5 numerical aperture (NA) objective. GFAP-positive cells were quantified by means of the automatic 
thresholding and segmentation features of ImageJ. The GFAP signal in immunostained sections was quanti-
fied using FIJI software (distributed by ImageJ, National Institutes of Health, Bethesda, MD, USA) by automatic 
thresholding images with the aid of the “Moments” algorithm.
Statistical analyses. Behavioral measurements were performed on 10 rats for each treatment carried out 
in 2 different experimental sets. For behavioral experiments standard ANOVA followed by Fisher’s protected 
least significant difference procedure were used. Histological, morphometric and immunohistochemical analyses 
were performed on 6 rats per group, evaluating 6 sections each of sciatic nerve and spinal cord for each animal. 
One-way repeated measure ANOVA followed by the Mann–Whitney test was used. All behavioral assessments 
were made by researchers blinded to rat treatment. Slides from control and experimental groups were labeled 
with numbers so that the person performing the image analysis was blinded as to the experimental group. In 
addition, all images were captured and analyzed by an investigator other than the one who performed measure-
ments to avoid possible bias. Data were analyzed using the “Origin 9.0” software (OriginLab, Northampton, MA, 
USA). Differences were considered significant at a P < 0.05.
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